Menu Search
Equities

Solasia Pharma KK

4597:TYO

Solasia Pharma KK

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)48.00
  • Today's Change-1.00 / -2.04%
  • Shares traded5.10m
  • 1 Year change+9.09%
  • Beta1.2775
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Solasia Pharma KK had revenues fall -43.50% from 1.09bn to 617.00m, though the company grew net income from a loss of 2.55bn to a smaller loss of 1.11bn.
Gross margin31.45%
Net profit margin-808.81%
Operating margin-808.81%
Return on assets-51.68%
Return on equity-61.22%
Return on investment-59.50%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Solasia Pharma KK fell by 75.00m. Cash Flow from Financing totalled 275.00m or 44.57% of revenues. In addition the company used 359.00m for operations while cash from investing was breakeven.
Cash flow per share-5.19
Price/Cash flow per share--
Book value per share9.85
Tangible book value per share4.80
More ▼

Balance sheet in JPYView more

Solasia Pharma KK has little financial risk as the capital structure does not rely on leverage.
Current ratio3.87
Quick ratio3.42
Total debt/total equity0.0224
Total debt/total capital0.0219
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.